VG-161 is under clinical development by Virogin Biotech and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VG-161’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VG-161 overview

VG-161 is under development for the treatment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, pancreatic ductal adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma, metastatic hepatocellular carcinoma, intrahepatic cholangiocarcinoma,  sarcoma, metastatic gastric or gastroesophageal junction adenocarcinoma,  bone sarcoma, soft tissue sarcoma, Ewing sarcoma and colon cancer. The drug candidate is an oncolytic virus.It is an attenuated herpes simplex virus type 1 (HSV-1), developed based on Virogin’s Synerlytic Platform, VG161 has a deletion of the ICP34.5 gene to prevent neurovirulence. It is administered through intratumor route. It acts by targeting interleukin-12, interleukin-15, interleukin-15 receptor subunit alpha and programmed cell death 1 ligand 1 (PD-L1).

Virogin Biotech overview

Virogin Biotech is a pharmaceutical company. It develops immunotherapies and oncolytic virotherapies that improve systemic antitumor immunity using oncolytic HSV-1 platform and Prime-Boost Approach. The company’s pipeline products include VG161, VG201, VG203, VG301, VGXXX. Its pipeline candidates treat Attenuated (ICP 34.5 deletion), and tumors. The company works in collaboration with research institutes, biotechnology, and pharmaceutical companies. It operates research and development hubs in Vancouver, Canada; and Shanghai, China. Virogin Biotech is headquartered in Vancouver, British Colombia, Canada.

For a complete picture of VG-161’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.